AU745759B2 - Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration - Google Patents

Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration Download PDF

Info

Publication number
AU745759B2
AU745759B2 AU16685/99A AU1668599A AU745759B2 AU 745759 B2 AU745759 B2 AU 745759B2 AU 16685/99 A AU16685/99 A AU 16685/99A AU 1668599 A AU1668599 A AU 1668599A AU 745759 B2 AU745759 B2 AU 745759B2
Authority
AU
Australia
Prior art keywords
och
formula
radical
represents hydrogen
benzenesulphimidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16685/99A
Other languages
English (en)
Other versions
AU1668599A (en
Inventor
Thomas Fahrig
Irene Gerlach
Ervin Horvath
Reinhard Jork
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU1668599A publication Critical patent/AU1668599A/en
Application granted granted Critical
Publication of AU745759B2 publication Critical patent/AU745759B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU16685/99A 1997-11-24 1998-11-11 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration Ceased AU745759B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19751949 1997-11-24
PCT/EP1998/007197 WO1999026621A1 (de) 1997-11-24 1998-11-11 Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration

Publications (2)

Publication Number Publication Date
AU1668599A AU1668599A (en) 1999-06-15
AU745759B2 true AU745759B2 (en) 2002-03-28

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16685/99A Ceased AU745759B2 (en) 1997-11-24 1998-11-11 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Country Status (30)

Country Link
US (2) US6235774B1 (enExample)
EP (1) EP1051170B1 (enExample)
JP (1) JP2001523716A (enExample)
KR (1) KR20010032357A (enExample)
CN (1) CN1134256C (enExample)
AR (1) AR016973A1 (enExample)
AT (1) ATE206615T1 (enExample)
AU (1) AU745759B2 (enExample)
BG (1) BG64167B1 (enExample)
CA (1) CA2311126A1 (enExample)
DE (2) DE19751949A1 (enExample)
DK (1) DK1051170T3 (enExample)
ES (1) ES2164465T3 (enExample)
HN (1) HN1998000169A (enExample)
HU (1) HUP0004369A3 (enExample)
IL (1) IL135904A (enExample)
IS (1) IS5496A (enExample)
MY (1) MY118414A (enExample)
NO (1) NO20002638L (enExample)
NZ (1) NZ504656A (enExample)
PE (1) PE134999A1 (enExample)
PL (1) PL340674A1 (enExample)
PT (1) PT1051170E (enExample)
RU (1) RU2217140C2 (enExample)
SI (1) SI1051170T1 (enExample)
SV (1) SV1998000138A (enExample)
TR (1) TR200001471T2 (enExample)
TW (1) TW524690B (enExample)
WO (1) WO1999026621A1 (enExample)
ZA (1) ZA9810668B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
ATE352302T1 (de) * 2001-07-26 2007-02-15 Merck Patent Gmbh Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
WO2003022269A1 (en) * 2001-09-12 2003-03-20 Merck Patent Gmbh Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
MX2020000523A (es) * 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468753A (en) * 1990-05-22 1995-11-21 Sanofi Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
EP0749970A1 (de) * 1995-06-19 1996-12-27 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
US6235774B1 (en) * 1997-11-24 2001-05-22 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468753A (en) * 1990-05-22 1995-11-21 Sanofi Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
EP0749970A1 (de) * 1995-06-19 1996-12-27 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
US6235774B1 (en) * 1997-11-24 2001-05-22 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Also Published As

Publication number Publication date
TR200001471T2 (tr) 2000-10-23
IL135904A0 (en) 2001-05-20
MY118414A (en) 2004-10-30
PL340674A1 (en) 2001-02-12
EP1051170B1 (de) 2001-10-10
JP2001523716A (ja) 2001-11-27
ZA9810668B (en) 1999-05-26
DE19751949A1 (de) 1999-05-27
NZ504656A (en) 2002-02-01
NO20002638D0 (no) 2000-05-23
ATE206615T1 (de) 2001-10-15
IL135904A (en) 2003-07-06
EP1051170A1 (de) 2000-11-15
TW524690B (en) 2003-03-21
HUP0004369A2 (hu) 2001-04-28
CN1279604A (zh) 2001-01-10
BG64167B1 (bg) 2004-03-31
PE134999A1 (es) 2000-03-05
WO1999026621A1 (de) 1999-06-03
HN1998000169A (es) 1999-11-03
PT1051170E (pt) 2002-02-28
SI1051170T1 (en) 2001-12-31
US20010018530A1 (en) 2001-08-30
US6235774B1 (en) 2001-05-22
NO20002638L (no) 2000-05-23
US6331561B2 (en) 2001-12-18
BG104466A (en) 2001-02-28
AU1668599A (en) 1999-06-15
CN1134256C (zh) 2004-01-14
DK1051170T3 (da) 2001-12-27
HUP0004369A3 (en) 2002-04-29
CA2311126A1 (en) 1999-06-03
RU2217140C2 (ru) 2003-11-27
AR016973A1 (es) 2001-08-01
DE59801724D1 (de) 2001-11-15
IS5496A (is) 2000-05-15
SV1998000138A (es) 1999-05-25
ES2164465T3 (es) 2002-02-16
KR20010032357A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
US6235774B1 (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
US4888347A (en) Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
US5426120A (en) Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
EP1248606A1 (de) Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten
WO2004047830A2 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
JP2001509173A (ja) 胃腸リパーゼ阻害剤の使用
EP0629400B1 (en) Idebenone compositions for treating Alzheimer's disease
DE69801661T2 (de) Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
JP7344422B2 (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
WO2000041700A1 (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
JP2003523385A (ja) 神経変性疾患の治療法
DE2823268C2 (enExample)
AU631989B2 (en) Novel application of 4-carbamoyl-1-beta-d-ribofuranosyl imidazolium-5-olate
JPH06502155A (ja) 脱髄性疾患の処置方法
HK1034661A (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
MXPA00005054A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
EP4045056A1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit clindamycin und artesunat
WO2005046666A1 (de) Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz
JPH1053526A (ja) 医薬組成物
WO2000010542A2 (de) Verwendung von pentaerythritylnitrate zusammen mit phosphodiesterase-v-hemmern, z.b. sildenafil

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)